TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Fleiss's kappa for SBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fleiss's kappa for WAT-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of NE and E
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of LGE positive segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: N-terminal brain natriuretic peptide level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nephrotoxicity incidence
Endpoint domain: Adverse events/effects
Primary endpoint: PCA PI and RI values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: RNFL thickness values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of glaucoma
Endpoint domain: Adverse events/effects
Primary endpoint: Seroconversion to MV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroresponse to YFV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rise in meningococcus A bactericidal titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rise in immunoglobulin A and G antibodies to rotavirus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: global insomnia severity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: sleep-onset insomnia severity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Improvement in appearance of photoaging lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Increased SC hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decreased TEWL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Likelihood of needing nutrition via TPN
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Serum levels of troponin T
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinary PYD levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Retching
Endpoint domain: Adverse events/effects
Primary endpoint: Total VTE incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Major or clinically relevant non-major bleeding incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Delivery efficiency of sore throat medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of the dose delivered to the mouth and throat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance rates from the mouth and throat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of hazardous drinking (AUDIT-C >=6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquiescence to trial participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: 2-h post-dose headache response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion success rates of induced ventricular fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: first febrile seizure recurrence
Endpoint domain: Mortality/survival
Primary endpoint: temperature reduction after fever onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month-point prevalence rate of postoperative macular pucker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic use rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPK‐MM levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum PC III levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the ROC curve for VTDR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for VTDR detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for VTDR detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with a ≥ 50% reduction in 28-day seizure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients who were seizure-free for the maintenance phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Global health scales improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physical functional scales
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Symptom scales improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: permeability to basic fuchsin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent increase in creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: risk of WRF
Endpoint domain: Adverse events/effects
Primary endpoint: length of the operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: time to return to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: degree of cosmetic satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fewer obstacles to recovery
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: DM exposure increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DX exposure increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Knee Function Questionnaire scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined rate of myocardial blush grade 3 and/or ST-segment resolution >50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PPI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PRI(R)T scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of analgesic tablets used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Risk of developing primary outcomes
Endpoint domain: Mortality/survival
Primary endpoint: USVL<1 copy/mL at W96
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: self-monitored blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: patient satisfaction with Welltang
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: school performance
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: absences
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: home environment
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: alpha‐1‐antitrypsin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Smoking intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tobacco burned per cigarette
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of T2DM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skin Conductance (SC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Blood Oxygen (BO) Variance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cost to diagnosis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Postchallenge serum bactericidal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of TNF-alpha after endotoxin challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of IL-6 after endotoxin challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of IL-8 after endotoxin challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HIV-1 RNA levels in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: humoral immunity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cellular immunity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Parental satisfaction with treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Airway seal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time until delivery of first tidal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hoarseness frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Mean percentage decrease in PASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of patients showing considerable improvement or clearing of psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 7-day abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prolonged 6-month abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anxiety and depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality-of-life analysis
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: submaximal arm ergometry power output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper body muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wounds healed without complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: clinically significant prostate cancer detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recovery time of sensory blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time of motor blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sedation score
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in glaucoma medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing of the ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of 8‐iso‐PGF2α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma levels of Gpx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in FGF23 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse outcomes in patients with established CAD
Endpoint domain: Adverse events/effects
Primary endpoint: Work resumption
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: clinically significant hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mDTSS (mean Daily Total Symptom Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events following immunization (AEFIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean duration of antibiotic exposure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Natural killer cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: reduction of periopathogenic bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalisation of plasma selenium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in total T4 and T3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in reverse T3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reactive airways (PD20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Full Scale IQ
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Child Behavior Checklist Total Problem Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: lunch intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breakfast intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TcPO2 at 30 minutes postapplication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak systolic velocity of the cavernous arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: acceleration time of the cavernous arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: preference for tadalafil mode
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Breast lump size score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs and symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean daily warfarin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International normalized ratio maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of blanching erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of nonblanching erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: PDR (Peripheral Dilation Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of cervical HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Clearance rate of HDL containing apoE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: adherence to guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation in the frontal, premotor, and primary visual cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Richer learning experience
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: SIAS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glu content in blood serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: calcium oxalate crystallization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of adverse reactions reported
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuation of study due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in levels of TNF‐α and IL‐6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in 13C‐metathetin breath test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of progress in liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postoperative stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cholesterol and apolipoprotein B levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Factor VII activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean diameter of the bile duct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Wound closure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vacc‐4x CD8+ T cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vacc‐4x IgA and IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain intensity on mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects (pruritus, nausea, vomiting)
Endpoint domain: Adverse events/effects
Primary endpoint: weeks missed due to non-contact knee injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: primary lower-limb muscle strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: micturition disorder-related QOL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: pain and micturition disorder
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sensitivity to the presence and type of endoleaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of human papillomavirus type 16 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: BOMP index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported flossing
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Nasal symmetry enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical control of asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall ERFC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumour marker elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in the number of anaerobic species in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Microbial outcomes
Primary endpoint: Reduction of tongue coating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VSC levels in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of voiding without catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean energy required for defibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Preference for family building options
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Children and adolescents' physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change toward healthy weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food preparation skills
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: TV viewing during meals
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Serum levels of 3‐Epi‐25‐OH‐D₃
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of dominant follicles (> or = 14 mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: compliance with nasal CPAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in daytime urine loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of elderly individuals with >25% decrease in daytime urine loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Care burden scale score of caregivers
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Axial length of the scaphoid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Axial length of the middle phalanx of ring finger
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of nasal axis deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of orbital-globe axis deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI for age maintenance or reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in YBOCS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impressions‐Improvement rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status